Yu Kurahara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yu Kurahara has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Asami Osugi
The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association
2 shared publications - Satoshi Mitarai
The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association
2 shared publications Atsushi Suzuki
Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Kumagaya City, Saitama, 360-0197, Japan
1 shared publicationDongjie Xu
Department of Respiratory Medicine, Japanese Red Cross Sendai Hospital, Sendai City, Miyagi, 982-0801, Japan
1 shared publicationHaruyuki Ishii
Department of Respiratory Medicine, Kyorin University Faculty of Medicine, Mitaka City, Tokyo, 181-8611, Japan
1 shared publicationHidekazu Matsushima
Department of Respiratory Medicine, Saitama Red Cross Hospital, Saitama city, Saitama, 330-0081, Japan
1 shared publication
Latest Publications
- Open Access
Analysis of publicly available genomic data
Ethambutol (EMB) is a vital drug for treating Mycobacterium avium-intracellulare (MAI) infections; however, the genomic mutations underlying EMB resistance in MAI remain unclear. Herein, we evaluated eight sets of MAI clinical isolates, each containing at least two serial isolates collected from the same patient who received EMB in Japan. In four sets, the isolates independently increased EMB MIC by 4-fold, coinciding with mutations in the upstream region of embA or those corresponding to Mycobacterium tuberculosis (Mtb) embB Met306Val and Gln497Arg. Based on the increased EMB MIC values, we defined normal and elevated EMB MICs as ?8 µg/mL and ?16 µg/mL, respectively. In the other four sets, all of the isolates had elevated EMB MICs. In silico promoter prediction and expression analysis indicated that the upstream region of embA corresponds to the embA?embB promoter region, and mutations in this region increased the transcription of embA and embB, increasing EMB MICs. Furthermore, the analysis of 60 epidemiologically unrelated strains revealed that isolates with mutations in the embA?embB promoter and at embB codons 306/497 exhibited significantly higher EMB MICs compared with those without mutations. Publicly available genomic data demonstrate the worldwide occurrence of these mutations in clinical isolates. These results establish an association between elevated EMB MICs and mutations at embB codons 306/497 and the embA?embB promoter and are expected to predict EMB resistance.
Open AccessAnalysis of publicly available genomic data
Ethambutol (EMB) is a vital drug for treating Mycobacterium avium-intracellulare (MAI) infections; however, the genomic mutations underlying EMB resistance in MAI remain unclear. Herein, we evaluated eight sets of MAI clinical isolates, each containing at least two serial isolates collected from the same patient who received EMB in Japan. In four sets, the isolates independently increased EMB MIC by 4-fold, coinciding with mutations in the upstream region of embA or those corresponding to Mycobacterium tuberculosis (Mtb) embB Met306Val and Gln497Arg. Based on the increased EMB MIC values, we defined normal and elevated EMB MICs as ?8 µg/mL and ?16 µg/mL, respectively. In the other four sets, all of the isolates had elevated EMB MICs. In silico promoter prediction and expression analysis indicated that the upstream region of embA corresponds to the embA?embB promoter region, and mutations in this region increased the transcription of embA and embB, increasing EMB MICs. Furthermore, the analysis of 60 epidemiologically unrelated strains revealed that isolates with mutations in the embA?embB promoter and at embB codons 306/497 exhibited significantly higher EMB MICs compared with those without mutations. Publicly available genomic data demonstrate the worldwide occurrence of these mutations in clinical isolates. These results establish an association between elevated EMB MICs and mutations at embB codons 306/497 and the embA?embB promoter and are expected to predict EMB resistance.
- Open Access
- 28 February 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (3) , ofaf118
Effects of Amikacin Liposome Inhalation Suspension and Amikacin Resistance Development in Patients With Refractory Mycobacterium avium Complex Pulmonary Disease
Background: Amikacin liposome inhalation suspension (ALIS) is key for treating refractory Mycobacterium avium complex pulmonary disease (MAC-PD). However, microbiological efficacy by subtype remains unknown. The frequency and mechanism of amikacin (AMK) resistance during ALIS administration are also unclear. Methods: We retrospectively analyzed data from refractory MAC-PD patients who received ALIS for at least 6 months as an adjunct to guideline-based therapy at the NHO Kinki Chuo Chest Medical Center. We investigated the efficacy of ALIS and analyzed gene expression and the frequency of AMK resistance. Results: We enrolled 44 patients (median age, 72.0 years): 19 (43.2%) with the noncavitary nodular bronchiectatic (NC-NB) subtype and 25 (56.8%) with the cavitary subtype. Overall, sputum culture conversion was 56.8% (25/44): 84.2% (16/19) in the NC-NB subtype and 36.0% (9/25) in the cavitary subtype (P = .001). During intermittent dosing, conversion occurred in 50.0% (9/18). In patients with C-reactive protein (CRP) ≥1 mg/dL, cavitary subtype, and clarithromycin (CLM) resistance, the risk ratio for persistently positive cultures was 10.81 (95% CI, 1.66–70.40) compared with those with CRP <1 mg/dL, NC-NB subtype, and CLM susceptibility. Of all participants, 15.9% (7/44) had isolates with AMK resistance (minimum inhibitory concentration ≥128 µg/mL), and of these 71.4% (5/7) had rrs mutations. Conclusions: Regimens that included ALIS achieved higher culture conversion in NC-NB than cavitary MAC-PD cases. High CRP levels, cavitary disease, and CLM resistance predicted persistent culture positivity. AMK resistance acquired during ALIS administration may limit treatment options for refractory MAC-PD.
- 28 February 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (3) , ofaf118
Open AccessEffects of Amikacin Liposome Inhalation Suspension and Amikacin Resistance Development in Patients With Refractory Mycobacterium avium Complex Pulmonary Disease
Background: Amikacin liposome inhalation suspension (ALIS) is key for treating refractory Mycobacterium avium complex pulmonary disease (MAC-PD). However, microbiological efficacy by subtype remains unknown. The frequency and mechanism of amikacin (AMK) resistance during ALIS administration are also unclear. Methods: We retrospectively analyzed data from refractory MAC-PD patients who received ALIS for at least 6 months as an adjunct to guideline-based therapy at the NHO Kinki Chuo Chest Medical Center. We investigated the efficacy of ALIS and analyzed gene expression and the frequency of AMK resistance. Results: We enrolled 44 patients (median age, 72.0 years): 19 (43.2%) with the noncavitary nodular bronchiectatic (NC-NB) subtype and 25 (56.8%) with the cavitary subtype. Overall, sputum culture conversion was 56.8% (25/44): 84.2% (16/19) in the NC-NB subtype and 36.0% (9/25) in the cavitary subtype (P = .001). During intermittent dosing, conversion occurred in 50.0% (9/18). In patients with C-reactive protein (CRP) ≥1 mg/dL, cavitary subtype, and clarithromycin (CLM) resistance, the risk ratio for persistently positive cultures was 10.81 (95% CI, 1.66–70.40) compared with those with CRP <1 mg/dL, NC-NB subtype, and CLM susceptibility. Of all participants, 15.9% (7/44) had isolates with AMK resistance (minimum inhibitory concentration ≥128 µg/mL), and of these 71.4% (5/7) had rrs mutations. Conclusions: Regimens that included ALIS achieved higher culture conversion in NC-NB than cavitary MAC-PD cases. High CRP levels, cavitary disease, and CLM resistance predicted persistent culture positivity. AMK resistance acquired during ALIS administration may limit treatment options for refractory MAC-PD.
- Open Access
- 15 September 2024
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 63 (18) , 2581-2582
Tuberculous Bronchostenosis Manifesting as the "CT Angiogram Sign"
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 15 September 2024
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 63 (18) , 2581-2582
Open AccessTuberculous Bronchostenosis Manifesting as the "CT Angiogram Sign"
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 25 August 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (6) , 963-969
Validation of a diagnostic flowchart for tuberculous pleurisy in pleural fluid with high levels of adenosine deaminase
- 25 August 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (6) , 963-969
Validation of a diagnostic flowchart for tuberculous pleurisy in pleural fluid with high levels of adenosine deaminase
- 21 March 2023
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 116 (7) , 540-541
Melanoptysis
Yu Kurahara, And Yasuaki Shimatani; Melanoptysis, QJM: An International Journal of Medicine, , hcad042, https://doi.org/10.1093/qjmed/hcad042
- 21 March 2023
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 116 (7) , 540-541
Melanoptysis
Yu Kurahara, And Yasuaki Shimatani; Melanoptysis, QJM: An International Journal of Medicine, , hcad042, https://doi.org/10.1093/qjmed/hcad042
- Open Access
- 10 June 2022
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 115 (8) , 540
Diabetic foot ulcer infection with Mycobacterium avium
Yu Kurahara; Diabetic foot ulcer infection with Mycobacterium avium, QJM: An International Journal of Medicine, , hcac140, https://doi.org/10.1093/qjmed/hcac140
- 10 June 2022
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 115 (8) , 540
Open AccessDiabetic foot ulcer infection with Mycobacterium avium
Yu Kurahara; Diabetic foot ulcer infection with Mycobacterium avium, QJM: An International Journal of Medicine, , hcac140, https://doi.org/10.1093/qjmed/hcac140
- Open Access
- 9 June 2022
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 115 (8) , 541-542
Cryptococcal pericarditis
Yu Kurahara; Cryptococcal pericarditis, QJM: An International Journal of Medicine, , hcac141, https://doi.org/10.1093/qjmed/hcac141
- 9 June 2022
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 115 (8) , 541-542
Open AccessCryptococcal pericarditis
Yu Kurahara; Cryptococcal pericarditis, QJM: An International Journal of Medicine, , hcac141, https://doi.org/10.1093/qjmed/hcac141
- Open Access
- 1 January 2022
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 62 (8) , 0333-22-1246
Fibrothorax in a Patient with Social Withdrawal
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 1 January 2022
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 62 (8) , 0333-22-1246
Open AccessFibrothorax in a Patient with Social Withdrawal
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 1 July 2021
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 60 (13) , 2155-2156
Massive Bronchorrhea
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 July 2021
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 60 (13) , 2155-2156
Open AccessMassive Bronchorrhea
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- Open Access
- 1 January 2021
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 60 (13) , 6450-20-2154
The "Detachment Process" of Aspergilloma Formation
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2021
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 60 (13) , 6450-20-2154
Open AccessThe "Detachment Process" of Aspergilloma Formation
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies